Anxiously awaiting an FDA decision this fall, Beren Therapeutics has added $300 million in new capital to help launch its rare disease drug.
Anxiously awaiting an FDA decision this fall, Beren Therapeutics has added $300 million in new capital to help launch its rare disease drug.
The biotech …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
As Regeneron’s cancer portfolio continues to suffer setbacks, the company is placing a bet in a different direction through a…
Lilly pays up to $1B for AlzeCure's small-molecule Alzheimer's candidate; Bial drops Parkinson's drug after Phase 2b miss;…
Parabilis Medicines, the decade-old and well-funded
Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for Huntington's…
Apogee Therapeutics secures up to $800 million royalty deal with Blackstone Life Sciences to fund Phase 3 trials of eczema drug…
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
